University Researchers Reveal Pandemic's Toll on Cancer Survival Rates
COVID-19 pandemic disruptions significantly worsened short-term cancer survival rates across the United States, according to a groundbreaking study published in JAMA Oncology on February 5, 2026. Led by researchers from the University of Kentucky's Markey Cancer Center and the Medical University of South Carolina's Hollings Cancer Center, the analysis of Surveillance, Epidemiology, and End Results (SEER) data highlights how delays in screening, diagnosis, and treatment led to thousands of excess deaths. This research underscores the critical role of academic institutions in tracking public health crises and informing policy.
The study examined over 1 million patients diagnosed with invasive cancers in 2020 and 2021, comparing their one-year cause-specific survival (CSS) rates to pre-pandemic trends from 2015 to 2019. Disruptions stemmed from overwhelmed healthcare systems, postponed routine screenings like mammograms and colonoscopies, and shifted priorities to manage surging COVID-19 cases. While long-term overall cancer mortality continued to decline thanks to decades of progress, these short-term setbacks reveal vulnerabilities exposed by the pandemic.
Screening and Diagnosis Plummeted During Peak Pandemic Waves
One of the primary drivers of worsened cancer survival rates was the dramatic drop in preventive screenings. In April 2020 alone, breast cancer screening volumes fell by 87 percent and cervical cancer screenings by 84 percent, according to Centers for Disease Control and Prevention (CDC) data. This led to fewer early detections, with cancer incidence rates plunging 8-10 percent in 2020 before partial recovery in 2021. Late-stage diagnoses, which carry poorer prognoses, increased as a result.
Treatment delays compounded the issue. Chemotherapy infusions, surgeries, and radiation sessions were deferred or modified to minimize viral exposure risks. University cancer centers, such as those at major research institutions, played pivotal roles in adapting protocols while maintaining essential care. However, these adaptations couldn't fully offset the backlog, contributing to the observed survival dips.
Detailed Breakdown of Survival Declines by Stage and Cancer Type
The JAMA Oncology study provides granular insights into how pandemic disruptions worsened cancer survival rates. For early-stage cancers, one-year CSS was 0.44 percentage points lower than expected in 2020 and 0.27 points lower in 2021. Late-stage cancers fared worse, with drops of 1.34 and 1.20 percentage points, respectively.
| Cancer Type | 2020 Early-Stage Drop (pp) | 2021 Late-Stage Drop (pp) |
|---|---|---|
| Colorectal | -1.08 | -1.48 |
| Pancreatic | - | -2.13 |
| Lung | - | -2.01 |
| Esophageal | -3.89 | - |
| Brain | -2.94 | - |
Low-survival cancers like pancreas, liver, esophagus, lung, and brain showed pronounced declines. High-incidence cancers such as breast, prostate, colorectal, and melanoma also suffered, with colorectal seeing 16.3 percent more deaths than expected. An earlier National Cancer Institute (NCI) analysis of SEER data reported all-site one-year relative survival falling from 82.3 percent in 2018 Q2 to 77.5 percent in 2020 Q2, with stomach cancer dropping 8.5 percentage points.
Excess Deaths and Long-Term Ramifications Quantified
These survival shortfalls translated to tangible losses: approximately 17,390 additional cancer-related deaths within one year of diagnosis during 2020-2021—9,162 in 2020 and 8,228 in 2021. Lung cancer alone accounted for nearly 2,000 excess deaths in 2021.Read the full JAMA study.
- Late diagnoses shifted to more advanced stages, reducing treatability.
- Treatment interruptions increased recurrence risks.
- Overloaded systems delayed multidisciplinary care at academic medical centers.
While overall U.S. cancer mortality declined per American Cancer Society 2025 reports, these pandemic-era effects may echo in future statistics, emphasizing the need for vigilant monitoring by university epidemiologists.
Disparities Amplified: Age, Race, and Access Gaps
Vulnerable groups bore the brunt. Patients aged 65 and older saw steeper declines, as did certain racial/ethnic minorities, including Asian/Pacific Islanders and American Indian/Alaska Natives. Rural patients, often served by university-affiliated outreach programs, faced compounded barriers like telemedicine limitations.
University of Kentucky researchers noted greater impacts in non-White populations, aligning with pre-existing healthcare inequities exacerbated by pandemic resource strains. This highlights the importance of diverse research teams in higher education to address such gaps.
Disruptions to University-Led Cancer Research and Clinical Trials
Beyond patient care, the pandemic halted lab work, paused clinical trials, and disrupted training at U.S. universities. The American Association for Cancer Research (AACR) documented widespread closures of research facilities, delaying breakthroughs in immunotherapy and precision medicine.AACR COVID Impact Report.
Junior faculty and postdocs—key to future innovations—faced career setbacks, with grant applications deferred and collaborations stalled. Yet, academic resilience shone through virtual pivots and accelerated data analysis, as seen in the rapid SEER studies from NCI-affiliated programs. Aspiring researchers can find opportunities to contribute at leading institutions through higher ed research jobs.
Recovery Trajectories and Ongoing Challenges
By 2021 Q3-Q4 and into 2022, survival rates rebounded toward pre-pandemic levels, per NCI data, as screening resumed and vaccines mitigated COVID risks. However, backlogs persist, particularly for colorectal and pancreatic cancers amenable to screening.
University cancer centers like UC Davis and CU Anschutz reported sustained drops in certain diagnoses, urging catch-up campaigns. Current 2026 trends show five-year survival hitting 70 percent overall, but pandemic cohorts lag.CDC Cancer and COVID-19.
Solutions from Academia: Rebuilding Resilience
Experts advocate for hybrid care models, AI-driven triage, and expanded tele-oncology—innovations spearheaded by university teams. Policy recommendations include bolstering NCI funding for SEER surveillance and training more oncologists.
- Invest in mobile screening units for underserved areas.
- Prioritize trial continuity with remote monitoring.
- Enhance workforce pipelines via faculty positions in oncology.
Professionals advancing in this field may benefit from academic CV tips tailored for research careers.
Future Outlook: Preparing Higher Education for Health Crises
These studies from University of Kentucky and NCI researchers equip higher education to lead preparedness. Integrating pandemic lessons into curricula ensures future physicians and scientists are ready. Explore university jobs in medical research to join this vital work. With proactive measures, the U.S. can safeguard hard-won gains in cancer survival.
For career guidance, visit our higher ed career advice hub or search rate my professor for insights on top oncology faculty.
.jpg&w=128&q=75)
